Promotes normal and healthy brain function, including memory and concentration*
Phase 3a PIONEER TEENS Trial Finds Oral Semaglutide Lowers HbA1c in Adolescents With Type 2 Diabetes Over the past two decades, the prevalence of type 2 diabetes among children and adolescents has increased substantially, yet treatment options for this population remain limited, underscoring a significant unmet need, Martin Holst Lange, MD, PhD, chief scientific officer and executive vice president of research and development at Novo Nordisk, said in the company announcement
the planned human bioavailability study, including its expected design, timing, scope, objectives, pharmacokinetic endpoints, safety and tolerability assessments, and potential results
Some women have reported delayed or missed periods while taking tirzepatide
Negligent misrepresentation: Lawsuits accuse Novo Nordisk of overstating the potential benefits of Ozempic while minimizing or obscuring some of its risks
Mounjaro has a favorable savings plan for those who have insurance but whose plans dont cover it